Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease

Edward L. Hannan, Chuntao Wu, Gary Walford, Alfred T. Culliford, Jeffrey P. Gold, Craig R. Smith, Robert S.D. Higgins, Russell E. Carlson, Robert H. Jones

Research output: Contribution to journalArticle

438 Citations (Scopus)

Abstract

BACKGROUND: Numerous studies have compared the outcomes of two competing interventions for multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and coronary stenting. However, little information has become available since the introduction of drug-eluting stents. METHODS: We identified patients with multivessel disease who received drug-eluting stents or underwent CABG in New York State between October 1, 2003, and December 31, 2004, and we compared adverse outcomes (death, death or myocardial infarction, or repeat revascularization) through December 31, 2005, after adjustment for differences in baseline risk factors among the patients. RESULTS: In comparison with treatment with a drug-eluting stent, CABG was associated with lower 18-month rates of death and of death or myocardial infarction both for patients with three-vessel disease and for patients with two-vessel disease. Among patients with three-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.80 (95% confidence interval [CI], 0.65 to 0.97) and the adjusted survival rate was 94.0% versus 92.7% (P=0.03); the adjusted hazard ratio for death or myocardial infarction was 0.75 (95% CI, 0.63 to 0.89) and the adjusted rate of survival free from myocardial infarction was 92.1% versus 89.7% (P<0.001). Among patients with two-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.71 (95% CI, 0.57 to 0.89) and the adjusted survival rate was 96.0% versus 94.6% (P=0.003); the adjusted hazard ratio for death or myocardial infarction was 0.71 (95% CI, 0.59 to 0.87) and the adjusted rate of survival free from myocardial infarction was 94.5% versus 92.5% (P<0.001). Patients undergoing CABG also had lower rates of repeat revascularization. CONCLUSIONS: For patients with multivessel disease, CABG continues to be associated with lower mortality rates than does treatment with drug-eluting stents and is also associated with lower rates of death or myocardial infarction and repeat revascularization.

Original languageEnglish (US)
Pages (from-to)331-341
Number of pages11
JournalNew England Journal of Medicine
Volume358
Issue number4
DOIs
StatePublished - Jan 24 2008

Fingerprint

Drug-Eluting Stents
Coronary Artery Bypass
Coronary Disease
Myocardial Infarction
Survival Rate
Confidence Intervals
Stents
Mortality
Coronary Artery Disease
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hannan, E. L., Wu, C., Walford, G., Culliford, A. T., Gold, J. P., Smith, C. R., ... Jones, R. H. (2008). Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. New England Journal of Medicine, 358(4), 331-341. https://doi.org/10.1056/NEJMoa071804

Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. / Hannan, Edward L.; Wu, Chuntao; Walford, Gary; Culliford, Alfred T.; Gold, Jeffrey P.; Smith, Craig R.; Higgins, Robert S.D.; Carlson, Russell E.; Jones, Robert H.

In: New England Journal of Medicine, Vol. 358, No. 4, 24.01.2008, p. 331-341.

Research output: Contribution to journalArticle

Hannan, EL, Wu, C, Walford, G, Culliford, AT, Gold, JP, Smith, CR, Higgins, RSD, Carlson, RE & Jones, RH 2008, 'Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease', New England Journal of Medicine, vol. 358, no. 4, pp. 331-341. https://doi.org/10.1056/NEJMoa071804
Hannan, Edward L. ; Wu, Chuntao ; Walford, Gary ; Culliford, Alfred T. ; Gold, Jeffrey P. ; Smith, Craig R. ; Higgins, Robert S.D. ; Carlson, Russell E. ; Jones, Robert H. / Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. In: New England Journal of Medicine. 2008 ; Vol. 358, No. 4. pp. 331-341.
@article{f5fb856c276446ba8fe32ddd557fe833,
title = "Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease",
abstract = "BACKGROUND: Numerous studies have compared the outcomes of two competing interventions for multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and coronary stenting. However, little information has become available since the introduction of drug-eluting stents. METHODS: We identified patients with multivessel disease who received drug-eluting stents or underwent CABG in New York State between October 1, 2003, and December 31, 2004, and we compared adverse outcomes (death, death or myocardial infarction, or repeat revascularization) through December 31, 2005, after adjustment for differences in baseline risk factors among the patients. RESULTS: In comparison with treatment with a drug-eluting stent, CABG was associated with lower 18-month rates of death and of death or myocardial infarction both for patients with three-vessel disease and for patients with two-vessel disease. Among patients with three-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.80 (95{\%} confidence interval [CI], 0.65 to 0.97) and the adjusted survival rate was 94.0{\%} versus 92.7{\%} (P=0.03); the adjusted hazard ratio for death or myocardial infarction was 0.75 (95{\%} CI, 0.63 to 0.89) and the adjusted rate of survival free from myocardial infarction was 92.1{\%} versus 89.7{\%} (P<0.001). Among patients with two-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.71 (95{\%} CI, 0.57 to 0.89) and the adjusted survival rate was 96.0{\%} versus 94.6{\%} (P=0.003); the adjusted hazard ratio for death or myocardial infarction was 0.71 (95{\%} CI, 0.59 to 0.87) and the adjusted rate of survival free from myocardial infarction was 94.5{\%} versus 92.5{\%} (P<0.001). Patients undergoing CABG also had lower rates of repeat revascularization. CONCLUSIONS: For patients with multivessel disease, CABG continues to be associated with lower mortality rates than does treatment with drug-eluting stents and is also associated with lower rates of death or myocardial infarction and repeat revascularization.",
author = "Hannan, {Edward L.} and Chuntao Wu and Gary Walford and Culliford, {Alfred T.} and Gold, {Jeffrey P.} and Smith, {Craig R.} and Higgins, {Robert S.D.} and Carlson, {Russell E.} and Jones, {Robert H.}",
year = "2008",
month = "1",
day = "24",
doi = "10.1056/NEJMoa071804",
language = "English (US)",
volume = "358",
pages = "331--341",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease

AU - Hannan, Edward L.

AU - Wu, Chuntao

AU - Walford, Gary

AU - Culliford, Alfred T.

AU - Gold, Jeffrey P.

AU - Smith, Craig R.

AU - Higgins, Robert S.D.

AU - Carlson, Russell E.

AU - Jones, Robert H.

PY - 2008/1/24

Y1 - 2008/1/24

N2 - BACKGROUND: Numerous studies have compared the outcomes of two competing interventions for multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and coronary stenting. However, little information has become available since the introduction of drug-eluting stents. METHODS: We identified patients with multivessel disease who received drug-eluting stents or underwent CABG in New York State between October 1, 2003, and December 31, 2004, and we compared adverse outcomes (death, death or myocardial infarction, or repeat revascularization) through December 31, 2005, after adjustment for differences in baseline risk factors among the patients. RESULTS: In comparison with treatment with a drug-eluting stent, CABG was associated with lower 18-month rates of death and of death or myocardial infarction both for patients with three-vessel disease and for patients with two-vessel disease. Among patients with three-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.80 (95% confidence interval [CI], 0.65 to 0.97) and the adjusted survival rate was 94.0% versus 92.7% (P=0.03); the adjusted hazard ratio for death or myocardial infarction was 0.75 (95% CI, 0.63 to 0.89) and the adjusted rate of survival free from myocardial infarction was 92.1% versus 89.7% (P<0.001). Among patients with two-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.71 (95% CI, 0.57 to 0.89) and the adjusted survival rate was 96.0% versus 94.6% (P=0.003); the adjusted hazard ratio for death or myocardial infarction was 0.71 (95% CI, 0.59 to 0.87) and the adjusted rate of survival free from myocardial infarction was 94.5% versus 92.5% (P<0.001). Patients undergoing CABG also had lower rates of repeat revascularization. CONCLUSIONS: For patients with multivessel disease, CABG continues to be associated with lower mortality rates than does treatment with drug-eluting stents and is also associated with lower rates of death or myocardial infarction and repeat revascularization.

AB - BACKGROUND: Numerous studies have compared the outcomes of two competing interventions for multivessel coronary artery disease: coronary-artery bypass grafting (CABG) and coronary stenting. However, little information has become available since the introduction of drug-eluting stents. METHODS: We identified patients with multivessel disease who received drug-eluting stents or underwent CABG in New York State between October 1, 2003, and December 31, 2004, and we compared adverse outcomes (death, death or myocardial infarction, or repeat revascularization) through December 31, 2005, after adjustment for differences in baseline risk factors among the patients. RESULTS: In comparison with treatment with a drug-eluting stent, CABG was associated with lower 18-month rates of death and of death or myocardial infarction both for patients with three-vessel disease and for patients with two-vessel disease. Among patients with three-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.80 (95% confidence interval [CI], 0.65 to 0.97) and the adjusted survival rate was 94.0% versus 92.7% (P=0.03); the adjusted hazard ratio for death or myocardial infarction was 0.75 (95% CI, 0.63 to 0.89) and the adjusted rate of survival free from myocardial infarction was 92.1% versus 89.7% (P<0.001). Among patients with two-vessel disease who underwent CABG, as compared with those who received a stent, the adjusted hazard ratio for death was 0.71 (95% CI, 0.57 to 0.89) and the adjusted survival rate was 96.0% versus 94.6% (P=0.003); the adjusted hazard ratio for death or myocardial infarction was 0.71 (95% CI, 0.59 to 0.87) and the adjusted rate of survival free from myocardial infarction was 94.5% versus 92.5% (P<0.001). Patients undergoing CABG also had lower rates of repeat revascularization. CONCLUSIONS: For patients with multivessel disease, CABG continues to be associated with lower mortality rates than does treatment with drug-eluting stents and is also associated with lower rates of death or myocardial infarction and repeat revascularization.

UR - http://www.scopus.com/inward/record.url?scp=38549177642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549177642&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa071804

DO - 10.1056/NEJMoa071804

M3 - Article

C2 - 18216353

AN - SCOPUS:38549177642

VL - 358

SP - 331

EP - 341

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 4

ER -